

New Test Announcement



Addition of Buprenorphine and Oxycodone to Drug Screen Testing Effective: February 22, 2017

Effective February 22, 2017, St. Luke's Laboratory will perform kit testing for Buprenorphine (Suboxone) and Oxycodone on all drug screens.

Qualitative VERDICT[®]-II Drugs of Abuse screens utilize a one-step, solid-phase immunoassay technology to provide a very rapid test requiring no instrumentation. It may be used to screen urine samples for the drug Buprenorphine (Suboxone) or Oxycodone prior to confirmatory testing.

It is recommended to order confirmatory testing if you are monitoring patients for drug compliance.

Test Name: Drug of Abuse Screen, With Confirmation (Test Code: DRUGABC)
Drug of Abuse Screen, No Confirmation (Test Code: DRUGABSCRN)

Sample Type: 60 mL from a random urine collection. Specimens should be refrigerated if testing is delayed for more than eight hours. No preservative.

Testing is available 24 hours a day, 7 days a week. Specimens will be retained in the laboratory for one week. If confirmation with quantification is desired, please phone the lab at 249-5200.

If you have questions, please contact Kristin Baer, M.D. Chemistry Medical Director (218)249-5208, Jennifer Viergutz, MBA, MA, MT(ASCP) (218)249-5724, Laboratory Operations Manager or Megan Harris, MLS(ASCP)(218)249-5207, Urology & Chemistry Technical Specialist.

See St. Luke's Laboratory Services Web page containing New Test Announcements:
<http://www.slhduluth.com/hospital/laboratory-services/>